FIGO/ICM guidelines for preventing Rhesus disease: A call to action

Visser, Gerard H.A.; Thommesen, Trude; Renzo, Gian Carlo Di; Nassar, Anwar H.; Spitalnik, Steven L.

doi:10.1002/ijgo.13459

Cited by 34 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Administration of RhD immune globulin is advised after every potential sensitizing event including molar pregnancies. Some guidelines suggest not to use RhD immune globulin for under 8 weeks pregnancy termination, but there is no consensus regarding this matter [26][27][28][29]. RhD alloimmunized patients do not benefit from RhD immune globulin administration but can avoid HDFN by obtaining a pregnancy using RhD negative donor sperm, in vitro fertilization with selected RhD negative embryo, for heterozygous fathers or by using a non alloimmunized gestational surrogate [27].…”

Section: Prevention Of Hdfnmentioning

confidence: 99%

Untitled

2022

Ro Med J.

View full text Add to dashboard Cite

Hemolytic disease of the fetus and newborn is a consequence of maternal immune response to fetal red blood cells antigens inherited from the father, that the mother does not possess, stimulated by antepartum or intrapartum fetomaternal hemorrhage. As a result, fetal erythrocytes are destroyed, leading to various degrees of anemia and hyperbilirubinemia, with high perinatal morbidity and mortality rates. This review's purpose is to reveal the importance of the alloantibodies beyond RhD and ABO system, the updated algorithms used in the diagnosis and management of the disease and the importance of RhD universal immune prophylaxis practice. For this purpose, the database from PubMed and UpToDate was searched for literature reviews, case studies, society guidelines and retrospective studies in English regarding hemolytic disease of the fetus and newborn from 2013 to March 2022. Anti D prophylaxis protocols, early diagnosis and proper intrauterine and postpartum treatment help significantly reduce the disease's burden.

show abstract

Section: Prevention Of Hdfnmentioning

confidence: 99%

Untitled

2022

Ro Med J.

View full text Add to dashboard Cite

show abstract

“…У нових рекомендаціях Канадського товариства акушерів та гінекологів (SOGC, 2018) [5], Міжнародної федерації гінекологів та акушерів (FIGO, 2021) [6], Австралійського національного управління крові (2021) [7] висвітлені основні підходи до вирішення даного питання.…”

Section: резус-конфликт: профилактируем по мировым стандартам ил куку...unclassified

RHESUS-CONFLICT: prevent according to world standards

Kukuruza

Titarenko

Vozniuk

et al. 2021

RHW

View full text Add to dashboard Cite

The article is devoted to the prevention of the development of rhesus-conflict. A literature review, clinical guidelines and recommendations for highlighting and discussing of this pathology are presented. The history of the formation of anti-rhesus immunoglobulin, the results of its first use in the pregnant women are described. The factors for predicting the risk of hemolytic disease of the fetus and newborn development, standards for the diagnosis of hemolytic anemia are given. The approaches to the management of this pathology, recommended by foreign professional societies of obstetricians and gynecologists, are presented. In the article there are the stages of rhesus-conflict prevention: antenatal prophylaxis at 28–34 weeks of gestation, postpartum prophylaxis if the newborn is Rh-positive, and the prophylaxis after pregnancy complications associated with prenatal fetal and maternal bleeding. The indications and doses of anti-rhesus immunoglobulin use during antenatal prophylaxis at 28–34 weeks of gestation are given. The management of postpartum prophylaxis is described in detail, which indicates the doses and method of administration of anti- rhesus immunoglobulin to non-immunized Rh-negative women in case of the birth of a Rh-positive child, the indications for increasing the dose of anti-Rh immunoglobulin are presented also. The importance of performing the Kleihauer-Betke test for assessing the volume of fetal maternal transfusion is described. The conditions during which the prevention of Rh-conflict is carried out after complications of pregnancy which are associated with prenatal fetal and maternal bleeding, anti-rhesus immunoglobulin are given. The approaches to the prevention of rhesus-conflict are considered, which are reflected in the clinical protocol for obstetric and gynecological care, which unites all the latest world recommendations.

show abstract

“…However, more than 50 years later this disease continues to be a killer in major parts of the world and to produce significant morbidity and mortality in children, estimated at more than 160 000 perinatal deaths and 100 000 cases of disability annually 3 . In the current guidelines 4 from FIGO, the International Confederation of Midwives (ICM), and the Worldwide Initiative for Rh Disease Eradication (WIRhE), the evidence regarding the usefulness of Anti‐Rh(D) immunoglobulin is revisited, taking into account its effectiveness, different doses used for different indications, and prioritizing its administration by indication. All agree that “there is still a long way to go.”…”

mentioning

confidence: 99%